Osteoporosis is a systemic bone metabolic disease with increased bone fragility and easy fracture that is common in middle-aged and elderly women and men. The most common symptoms are pain, shortened height, easy to fall, and slow and awkward walking. Once a fracture occurs, it will cause more physical symptoms and seriously affect human health, and even life-threatening for the elderly.
Primary osteoporosis can be divided into three stages of low bone mass, osteoporosis and severe osteoporosis according to the severity.
Osteoporosis is a chronic and invisible disease, and patient compliance with medication and monitoring of treatment indicators are relatively common problems. Obtaining better treatment effects, reducing the incidence of adverse reactions, and controlling the risk of treatment are issues of common concern for doctors and patients.
At present, the main drugs for the treatment of osteoporosis are calcitonins, bisphosphonates, estrogen and its receptor modulators, vitamin K, parathyroid hormone, etc. Vitamin D and various calcium agents are basic nutritional preparations . The doctor will choose the treatment plan according to the patient's disease and comprehensive factors
Bisphosphonate drugs are the first-line drugs for the treatment of osteoporosis. The basic principle is to inhibit bone resorption and regulate the negative balance in bone metabolism. Alendronic acid and zoledronic acid are already on the market.
Minodronic acid (the important intermediate is Ethyl trans-4-oxo-2-butenoate CAS 2960-66-9) is a bisphosphonate drug first marketed in Japan in 2004, which is characterized by a therapeutic dose of alendronic acid One-tenth, clinical research is mainly based on the Asian population, so this kind of medicine may be more beneficial to patients in China.